Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$89.78

-2.43 (-2.64%)

08:46
04/09/18
04/09
08:46
04/09/18
08:46

AbbVie announces 'positive' results from Phase 3 SELECT-COMPARE clinical trial

AbbVie announced positive top-line results from the Phase 3 SELECT-COMPARE clinical trial showing that after 12 weeks, upadacitinib (15 mg, once-daily) met the primary endpoints of ACR20a and clinical remissionb versus placebo. All ranked secondary endpoints were also achieved versus either placebo or adalimumab (40 mg every other week). The ongoing study evaluates upadacitinib, an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis who are on a stable background of methotrexate and had an inadequate response. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

  • 14

    Apr

  • 26

    Apr

  • 08

    May

ABBV AbbVie
$89.78

-2.43 (-2.64%)

03/23/18
BMOC
03/23/18
NO CHANGE
Target $80
BMOC
Underperform
AbbVie price target lowered to $80 as uncertainty increases, says BMO Capital
BMO Capital analyst Alex Arfaei lowered AbbVIe estimates and reduced its price target to $80 from $95 on reduced Rova-T and Humira expectations. The analyst is concerned Rova-T's efficacy may not be meaningfully differentiated versus chemotherapy and lowered his Humira forecasts by 3% starting in 2020 because of greater expectations for biosimilar-driven price erosion. Arfaei reiterated his Underperform rating and said he is skeptical AbbVie revenue can grow given Humira erosion combined with lower expectations for the pipeline.
03/29/18
JEFF
03/29/18
NO CHANGE
Target $172
JEFF
Buy
Shire investors may be amenable to $50B-plus bid, says Jefferies
With challenges in the hemophilia market near term, Shire (SHPG) investors could be amenable to another $50B-plus bid, similar to AbbVie's (ABBV) 2014 offer, Jefferies analyst David Steinberg tells investors in a research note. This would represent a 35% premium to Shire's recent near five-year low valuation, the analyst writes. He says "it remains to be seen" how Takeda Pharmaceutical (TKPYY) could structure a transaction for Shire given the companies' similar equity valuations. The analyst finds it possible that Takeda's disclosed interest could spark competitive bids from large cap pharma companies. He keeps a Buy rating on Shire with a $172 price target.
04/05/18
LEHM
04/05/18
NO CHANGE
LEHM
Barclays upgrades Merck, downgrades Biogen and Pfizer in sector reassessment
Barclays analyst Geoff Meacham made some rating changes while reassessing the Biopharmaceutical sector. Biopharma sentiment has been negative since the start of 2018, despite a modest pick-up in deals and diminished rhetoric on drug pricing, Meacham tells investors in a research note titled "U.S. Biopharmaceuticals: Where to from here?" The analyst believes "more transformative" acquisitions, "clean" Phase 3 wins, and even a relatively strong Q1 earnings season could help "re-rate the sector" and get investors more engaged in the group. Ahead of the Q1 earnings season, Meacham upgraded Merck (MRK) to Overweight from Equal Weight and downgraded to Equal Weight from Overweight shares of Biogen (BIIB), Pfizer (PFE), Biohaven Pharmaceutical (BHVN) and Myovant Sciences (MYOV). The analyst also lowered his price target for Equal Weight-rated AbbVie (ABBV) to $102 from $120, for Equal Weight-rated Amgen (AMGN) to $180 from $180, for Overweight-rated Prothena (PRTA) to $50 from $70 and for Overweight-rated Incyte (INCY) to $135 from $165.
04/06/18
GSCO
04/06/18
NO CHANGE
Target $135
GSCO
Buy
AbbVie management remains confident in stem platform, says Goldman Sachs
Goldman Sachs analyst Jami Rubin kept her Buy rating and $135 price target on AbbVie, saying that in her latest investor meetings with the company, the management was "stunned" by the magnitude of market cap lost after the topline results of TRINITY on March 22nd. Despite the disappointing trial data, Rubin says that AbbVie management remains confident in its stem platform as its "single agent activity and clean safety profile" validate the therapy. Rubin also believes that the market overreacted, wrongly interpreting the FDA decision by removing the entire Rova-T and stem platform opportunity from AbbVie's valuation model.

TODAY'S FREE FLY STORIES

EEM

iShares MSCI Emerging Markets ETF

$41.78

0.26 (0.63%)

06:46
08/17/18
08/17
06:46
08/17/18
06:46
Technical Analysis
iShares MSCI Emerging Markets ETF: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWW

iShares MSCI Mexico

$49.18

-0.055 (-0.11%)

06:45
08/17/18
08/17
06:45
08/17/18
06:45
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$25.59

-0.01 (-0.04%)

06:44
08/17/18
08/17
06:44
08/17/18
06:44
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDN

PowerShares DB US Dollar Index Down

$21.16

(0.00%)

06:44
08/17/18
08/17
06:44
08/17/18
06:44
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$54.27

-0.07 (-0.13%)

, EQGP

EQT GP

$22.25

0.2 (0.91%)

06:43
08/17/18
08/17
06:43
08/17/18
06:43
Recommendations
EQT Midstream Partners, EQT GP analyst commentary  »

EQT Midstream price…

EQM

EQT Midstream Partners

$54.27

-0.07 (-0.13%)

EQGP

EQT GP

$22.25

0.2 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$49.85

0.61 (1.24%)

06:41
08/17/18
08/17
06:41
08/17/18
06:41
Recommendations
EQT Corporation analyst commentary  »

EQT Corporation price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COT

Cott Corp.

$15.64

0.13 (0.84%)

06:37
08/17/18
08/17
06:37
08/17/18
06:37
Initiation
Cott Corp. initiated  »

Cott Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$0.03

-0.0172 (-36.44%)

06:36
08/17/18
08/17
06:36
08/17/18
06:36
Periodicals
MoviePass puts additional restrictions on subscribers, NY Post says »

MoviePass chief Mitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFET

Safe-T

$0.00

(0.00%)

06:36
08/17/18
08/17
06:36
08/17/18
06:36
Syndicate
Safe-T raises $7.335M in a registered direct offering »

Safe-T announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$32.83

0.44 (1.36%)

, FB

Facebook

$174.76

-4.78 (-2.66%)

06:33
08/17/18
08/17
06:33
08/17/18
06:33
Periodicals
Twitter CEO criticizes Facebook, YouTube for Alex Jones' removal, BI reports »

Twitter (TWTR) CEO Jack…

TWTR

Twitter

$32.83

0.44 (1.36%)

FB

Facebook

$174.76

-4.78 (-2.66%)

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 06

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

AZRE

Azure Power

$15.95

-0.405 (-2.48%)

06:30
08/17/18
08/17
06:30
08/17/18
06:30
Initiation
Azure Power initiated  »

Azure Power initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HNHPF

Hon Hai Precision

$0.00

(0.00%)

, AAPL

Apple

$213.49

3.21 (1.53%)

06:26
08/17/18
08/17
06:26
08/17/18
06:26
Periodicals
Foxconn to launch semiconductor plant in China's Pearl River Delta, WSJ says »

Foxconn Technology, …

HNHPF

Hon Hai Precision

$0.00

(0.00%)

AAPL

Apple

$213.49

3.21 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUMC

Yum China

$35.33

0.29 (0.83%)

06:26
08/17/18
08/17
06:26
08/17/18
06:26
Downgrade
Yum China rating change  »

Yum China downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

LGND

Ligand

$239.84

-7.88 (-3.18%)

06:25
08/17/18
08/17
06:25
08/17/18
06:25
Initiation
Ligand initiated  »

Ligand initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

, GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

06:24
08/17/18
08/17
06:24
08/17/18
06:24
Periodicals
Google CEO responds to criticism over plan for search engine in China, WSJ says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,206.00

-7.65 (-0.63%)

GOOGL

Alphabet Class A

$1,223.55

-8.75 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

BXG

Bluegreen Vacations

$20.39

-0.65 (-3.09%)

06:22
08/17/18
08/17
06:22
08/17/18
06:22
Downgrade
Bluegreen Vacations rating change  »

Bluegreen Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:21
08/17/18
08/17
06:21
08/17/18
06:21
Earnings
Deere reports Q3 EPS 2.78, consensus $2.75 »

Reports Q3 worldwide net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

WMT

Walmart

$98.63

8.39 (9.30%)

, COST

Costco

$223.20

1.55 (0.70%)

06:20
08/17/18
08/17
06:20
08/17/18
06:20
Recommendations
Walmart, Costco, Target analyst commentary  »

Walmart price target…

WMT

Walmart

$98.63

8.39 (9.30%)

COST

Costco

$223.20

1.55 (0.70%)

TGT

Target

$82.07

1.38 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 04

    Oct

KORS

Michael Kors

$71.94

0.63 (0.88%)

06:20
08/17/18
08/17
06:20
08/17/18
06:20
Recommendations
Michael Kors analyst commentary  »

Michael Kors price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

ENB

Enbridge

$34.89

-0.19 (-0.54%)

06:18
08/17/18
08/17
06:18
08/17/18
06:18
Upgrade
Enbridge rating change  »

Enbridge upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$53.58

1.24 (2.37%)

06:17
08/17/18
08/17
06:17
08/17/18
06:17
Recommendations
Dave & Buster's analyst commentary  »

Dave & Buster's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:16
08/17/18
08/17
06:16
08/17/18
06:16
Hot Stocks
Deere CEO says 'continue face cost pressures for raw materials and freight' »

"Deere's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

FB

Facebook

$174.76

-4.78 (-2.66%)

06:15
08/17/18
08/17
06:15
08/17/18
06:15
Periodicals
Facebook begins to crack down on opioid dealers, TechCrunch reports »

Facebook's internal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 06

    Sep

  • 18

    Sep

TM

Toyota

$122.76

0.9 (0.74%)

06:14
08/17/18
08/17
06:14
08/17/18
06:14
Periodicals
Toyota to boost production capacity in China by 20%, Reuters says »

Toyota will add more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$137.38

1.68 (1.24%)

06:13
08/17/18
08/17
06:13
08/17/18
06:13
Earnings
Deere sees FY18 equipment revenue up about 30%, consensus $33.78B »

Company equipment sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.